(Q34208140)

31 July 2017

1 reference

title

Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment (English)

1 reference

31 July 2017

1 reference

Paul DeRose

1

1 reference

31 July 2017

Philip E Thorpe

series ordinal

2

1 reference

31 July 2017

David E Gerber

series ordinal

3

1 reference

31 July 2017

language of work or name

1 reference

1 August 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

3

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

933-944

1 reference

VEGF inhibitors in cancer therapy

31 July 2017

cites work

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

Vascular disrupting agents in clinical development

21 January 2018

1 reference

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

21 January 2018

1 reference

21 January 2018

Cancer statistics, 2010

1 reference

Challenges for patient selection with VEGF inhibitors

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion

21 January 2018

1 reference

Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl

21 January 2018

1 reference

Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells

21 January 2018

1 reference

Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy

21 January 2018

1 reference

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice

21 January 2018

1 reference

Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF

21 January 2018

1 reference

Phosphatidylserine regulates the maturation of human dendritic cells.

21 January 2018

1 reference

A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice

21 January 2018

1 reference

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice

21 January 2018

1 reference

Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases

21 January 2018

1 reference

Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines

21 January 2018

1 reference

Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey

21 January 2018

1 reference

Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

21 January 2018

1 reference

EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer

21 January 2018

1 reference

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

21 January 2018

1 reference

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

MAGE A3 antigen-specific cancer immunotherapeutic

21 January 2018

1 reference

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

Management of venous thromboembolism in patients with primary and metastatic brain tumors

21 January 2018

1 reference

21 January 2018

1 reference

Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma

21 January 2018

1 reference

Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids

21 January 2018

1 reference

Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells

21 January 2018

1 reference

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.11.87

1 reference

31 July 2017

1 reference